The relationship between fear of cancer recurrence and health behaviors: A nationwide longitudinal study of cancer survivors.

2019 ◽  
Vol 38 (7) ◽  
pp. 596-605 ◽  
Author(s):  
Caroline Séguin Leclair ◽  
Sophie Lebel ◽  
J. Lee Westmaas
Keyword(s):  
Longitudinal Study ◽  
Health Behaviors ◽  
Cancer Survivors ◽  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Fear Of Cancer ◽  
The Relationship

scholarly journals Interpretation Bias in Breast Cancer Survivors Experiencing Fear of Cancer Recurrence

2021 ◽  
Vol 12 ◽  
Author(s):  
Malwina Tuman ◽  
Kailey E. Roberts ◽  
Geoffrey Corner ◽  
Courtney Beard ◽  
Carol Fadalla ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Cancer Recurrence ◽  
Somatic Symptoms ◽  
Interpretation Bias ◽  
Fear Of Cancer Recurrence ◽  
Background Information ◽  
Fear Of Cancer ◽  
The Relationship

Introduction: Fear of cancer recurrence (FCR) is a prevalent and persistent challenge that many cancer survivors endure. While the role of interpretation bias, a tendency to perceive ambiguous situations as threatening, has been established in the onset and maintenance of FCR, few studies have examined cancer-related interpretation bias specifically. Grounded in the cognitive formulation of FCR, the current study aimed to fill this gap by investigating the relationship between cancer-related interpretation bias, FCR, and somatic symptoms, and examining whether bias mediates the relationship between somatic symptoms and FCR.Materials and Methods: This study used baseline data from a randomized controlled trial of a cognitive bias modification intervention. Breast cancer survivors (n = 110) provided demographic and medical background information as well as self-report measures of FCR and severity of somatic symptoms. A computer-based assessment of interpretation bias was used to measure cancer-related interpretation bias on several bias indices: percentage of cancer-related threat endorsement, and percentage of benign endorsement; mean reaction time (RT) for threat, and mean RT for benign endorsement.Results: Higher threat endorsement was linked to higher Overall Fear and emerged as a mediator of the relationship between overall somatic symptoms and Overall Fear. We also found that older age was related to longer benign endorsement RT.Conclusion: This study contributes understanding of factors related to cancer-related interpretation bias and provides evidence that bias may influence the relationship between somatic symptoms and FCR in cancer survivors.

scholarly journals The relationship between illness representations, risk perception and fear of cancer recurrence in breast cancer survivors

2016 ◽  
Vol 26 (9) ◽  
pp. 1270-1277 ◽  
Author(s):  
Laurie A. Freeman-Gibb ◽  
Nancy K. Janz ◽  
Maria C. Katapodi ◽  
Brian J. Zikmund-Fisher ◽  
Laurel Northouse
Keyword(s):  
Breast Cancer ◽  
Risk Perception ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Cancer Recurrence ◽  
Illness Representations ◽  
Fear Of Cancer Recurrence ◽  
Fear Of Cancer ◽  
The Relationship

scholarly journals Perilla Oil and Bifidobacterium for Alleviating Fear of Cancer Recurrence in Breast Cancer Survivors: Study Protocol for a Three-Arm Phase II Randomized Controlled Study (POB Study)

2021 ◽  
Vol 4 (3) ◽  
pp. 46
Author(s):  
Yohei Sasaki ◽  
Mina Honyashiki ◽  
Takayuki Kinoshita ◽  
Akira Matsui ◽  
Ayako Nakashoji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Phase Ii ◽  
Study Protocol ◽  
Breast Cancer Survivors ◽  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Randomized Controlled ◽  
Perilla Oil ◽  
Fear Of Cancer

The fear of cancer recurrence (FCR) is the most common and most severe unmet need among cancer survivors. Safe treatments for the FCR that are easily disseminated are greatly needed. Our primary aim is a preliminary evaluation of the efficacy and effect size of perilla oil, which is rich in omega-3 fatty acids, and Bifidobacterium, a probiotic, on FCR in breast cancer survivors after the completion of chemotherapy. This study has been planned as an exploratory clinical study (phase II) and will be conducted as a three-arm, 12-week parallel group, masked-rater randomized controlled trial. Fifteen participants will be randomized with 1:1:1 allocation to receive Bifidobacterium plus perilla oil, Bifidobacterium alone, or no intervention (control). Interventions will end within 12 weeks after the random allocation of each participant. The participants will be outpatients with invasive breast cancer aged 20 years or older whose chemotherapy was completed at least 6 months before registration; hormone therapy may be ongoing. The primary outcome will be severity of FCR at 12 weeks assessed by masked raters using the 4-item Concerns about Recurrence Scale concerning overall fear of recurrence. The study protocol for the current study is registered in the Japan Registry of Clinical Trials (jRCTs031200029).

Sign in / Sign up

Export Citation Format

Share Document